- PLATFORM LOGINS
- |
- CONTACT
- Request a Demo
-
Continued Relationships with Health Insurers Reflect the Need for High-quality, High-value Care as
Eviti Connect streamlined the pre-authorization process for cancer treatments and reduced denials and appeals for this leading
“Implementation of the Affordable Care Act has resulted in a much more diverse Medicaid population,” said Dr.
The Medicaid health plan experienced compelling results in their two-state pilot program. During the two-year pilot, which covered approximately 250,000 members, the insurer noted a significant improvement in the use of evidence-based medicine for member oncology care as a result of providers submitting treatment requests via Eviti Connect. The successful pilot led the insurer to expand the program from two to 10 U.S. states.
For Eviti Connect to continue to help assure quality, high-value care for members with cancer, the non-profit, rural health plan signed a three-year renewal agreement. Under terms of the agreement, the health plan’s provider network will continue to benefit from Eviti Connect decision support solution, which includes evidence-based treatment regimens, condition-specific clinical trial options, and the potential for more efficient preauthorization and expedited reimbursement.
“This renewal of Eviti Connect by a large health plan demonstrates our continued leadership in delivering solutions that align the priorities of physicians, patients, and payers at the moment of clinical prescribing to promote the best care for patients,” said
NantHealth’s Eviti Connect is a web-based healthcare payer solution that electronically connects health plans and oncology practices for the authorization of treatment plans in near real-time. Eviti Connect reduces the administrative time involved in obtaining authorizations at the drug level, assures appropriate reimbursement at the regimen level, and validates cancer treatment options overall. It also provides the ability to have peer-to-peer conversations between prescribing oncologists and
About
This news release contains certain statements of a forward-looking nature relating to future events or future business performance. Forward-looking statements can be identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “plans,” “will,” “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. Risks and uncertainties include, but are not limited to: our ability to successfully integrate a complex learning system to address a wide range of healthcare issues; our ability to successfully amass the requisite data to achieve maximum network effects; appropriately allocating financial and human resources across a broad array of product and service offerings; raising additional capital as necessary to fund our operations; achieving significant commercial market acceptance for our sequencing and molecular analysis solutions; establish relationships with key thought leaders or payers’ key decision makers in order to establish our sequencing and molecular analysis solutions as a standard of care for patients with cancer; our ability to grow the market for our systems infrastructure and applications; successfully enhancing our systems infrastructure and applications to achieve market acceptance and keep pace with technological developments; customer concentration; competition; security breaches; bandwidth limitations; our ability to continue our relationship with
View source version on businesswire.com: https://www.businesswire.com/news/home/20200227005286/en/
Jen@nant.com
562-397-3639
Source: